NICE Single Technology Appraisal Guidance No 258 –
Erlotinib for the first-line treatment of locally advanced or
metastatic EGFR-TK mutation-positive non-small-cell lung
cancer
This NICE guidance was published on 27 June 2012. The web
reference for the appraisal and other related documents is:
www.nice.org.uk/TA258
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (749/11) on
this medication for this indication in January 2012. This stated
that:
erlotinib (Tarceva®) is accepted for use within
NHSScotland for the first-line treatment of patients with locally
advanced or metastatic non-small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) activating mutations.
Access the advice of SMC:
3. There is no material difference between the
recommendations of the NICE STA and SMC. Both pieces of advice are
based upon the application of a Patient Access Scheme.
If you need further assistance, please contact
Eleanor Brownlee in the first instance (tel 0141 225 6873 or email
eleanor.brownlee@nhs.net).
Published Date: 27 June 2012
